Key Takeaways for Illumina Stock
- Revenue reached $1.09 billion in Q1 2026, up 5% year-over-year and $20 million above the midpoint of guidance.
- Non-GAAP operating margin expanded to 22% in Q1 2026, up approximately 150 basis points year-over-year, with full-year guidance raised to 23% to 24%.
- Clinical sequencing consumables grew 20% ex-China for the second consecutive quarter, now representing more than 65% of total sequencing consumables revenue.
- TIKR’s mid-case values Illumina stock at approximately $228 by December 2030, implying around 41% total return from the current price of $162.
NovaSeq X Placements Hit 80 in Q1 2026 as Illumina’s Clinical Engine Pulls Away from Research Headwinds
Illumina (ILMN), the San Diego-based maker of DNA sequencing instruments and consumables used in research labs, hospitals, and clinical diagnostic workflows, delivered Q1 2026 results that cleared every guidance target and prompted a raise to the full-year outlook, with the engine behind the beat sitting squarely in its clinical sequencing business.
Q1 revenue of $1.09 billion came in $20 million above the midpoint of guidance, driven primarily by stronger-than-expected placements of the NovaSeq X, Illumina’s flagship high-throughput sequencing instrument designed to lower cost per genome and support clinical-scale sequencing workloads.
The company placed over 80 NovaSeq X units in the quarter, approximately 20 more than in Q1 2025 and well above the targeted range of 50 to 60 per quarter that management had communicated entering the year.
CFO Ankur Dhingra confirmed on the Q1 call that demand was so strong the company was actually supply constrained: “In fact, during Q1, we were supply constrained on the number of NovaSeq X units that were placed as the demand continues to remain very robust.”
The driver behind that demand is clinical adoption. Clinical sequencing consumables grew 20% ex-China for the second consecutive quarter, with more than 65% of total sequencing consumables revenue now coming from clinical applications including comprehensive genomic profiling, rare disease whole genome sequencing, and next-generation prenatal testing.
CEO Jacob Thaysen called out the platform transition as a structural tailwind rather than a one-quarter event: new multiunit clinical orders, expansion of regulated assays onto the X platform, and the 6-month lag between instrument placement and consumables pull-through all point toward a second-half ramp that is already partially baked into the installed base.
Research and applied consumables declined 12% ex-China in the quarter, reflecting continued NIH funding uncertainty, but management was explicit that this segment is not built into the guidance upside and could represent incremental lift if the funding environment stabilizes.
Illumina Stock’s Operating Margin Inflects as Clinical Mix Shifts the Cost Structure
Illumina stock’s revenue growth in Q1 2026 tells only part of the story. The more important development is what happened below the gross profit line.
Gross margin came in at 68% for the quarter, up 80 basis points year-over-year, as cost efficiencies and higher revenue partially offset tariff headwinds on electronic components and freight.
The gap between gross margin and operating margin narrowed meaningfully: non-GAAP operating income of $239 million translated to an operating margin of 22%, up approximately 150 basis points year-over-year, as total non-GAAP operating expenses of $506 million grew only 3% against a 5% revenue increase.
That operating leverage ratio, revenue growing faster than total operating expenses, is the mechanism the income statement has been building toward since operating margin troughed at negative 2% in Q2 2024.
From that trough, operating margin has now expanded sequentially over the following seven quarters, reaching 22% in Q1 2026, a recovery of more than 23 percentage points from the bottom.
SG&A held flat quarter-over-quarter at $280 million, and R&D spending of $240 million in Q1 2026 was up modestly from prior quarters but remained within the envelope of the company’s cost discipline program, reflecting the addition of the SomaLogic team rather than acceleration of underlying spend.
The full-year operating margin guidance of 23% to 24% implies the company expects to exit 2026 at an operating margin level roughly 350 basis points above where it ended 2025, a meaningful compounding of the structural improvement already visible in the trailing eight quarters of income statement data.
Illumina Stock Trails Agilent on Operating Margins, but the Recovery Gap Is Closing Fast
Illumina stock’s operating margin of 18% in Q1 2026 sits below both Thermo Fisher Scientific (TMO) at 18% and Agilent Technologies (A) at 24% for the same quarter, placing ILMN at the bottom of this peer group on a trailing basis.
The more important data point is the trajectory. Illumina stock’s operating margin was negative 2% in Q2 2024 while both TMO and Agilent held positive margins throughout that period, meaning the gap the market is still discounting reflects a trough that is already eight quarters in the past.
Agilent’s operating margin has ranged between 23% and 27% over the trailing eight quarters, a structurally wider band than ILMN’s current level, but Illumina stock’s 2026 full-year guidance of 23% to 24% operating margin would close that gap to near parity with Agilent’s most recent quarter of 24% and would pull ahead of TMO’s Q1 2026 reading of 18%.
Is Illumina Stock Undervalued in 2026? TIKR’s $297 Mid-Case Says the Operating Leverage Isn’t Priced In
TIKR’s mid case values Illumina stock at approximately $228 by December 2030, implying around 83% total return from the current price of $162, or roughly 8% annualized over 4.6 years.
If clinical consumables sustain double-digit growth through 2027 and the platform transition enables the company to hit its high single-digit revenue growth target, the high case reaches approximately $365, implying around 124% total return or roughly 10% annualized.
If research market weakness persists longer than guidance assumes and the NIH funding environment does not normalize, compressing the revenue ramp, the low case arrives at approximately $236, still implying around 45% total return or roughly 4% annualized.
The mid-case assumes neither full research recovery nor further deterioration, grounding the thesis entirely in the clinical consumables trajectory and the cost structure improvement already visible in the trailing eight quarters of income statement data.
Should You Invest in Illumina, Inc.?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up Illumina, Inc. stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track Illumina, Inc. alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze ILMN stock on TIKR for Free →
